IOVANCE BIOTHERAPEUTICS Business Summary

Iovance Biotherapeutics is a commercial-stage biotechnology company specializing in the development and commercialization of autologous tumor-infiltrating lymphocyte (TIL) therapies for metastatic cancer. The company generates revenue primarily through the direct sale of its flagship FDA-approved product, Amtagvi (lifileucel), the first cellular therapy indicated for advanced melanoma, and maintains a robust pipeline targeting non-small cell lung cancer (NSCLC) and cervical cancer. Its business model is centered on a high-value, personalized medicine approach where patient-specific T cells are expanded at its proprietary Iovance Cell Therapy Center (iCTC) and re-infused as a one-time curative-intent treatment. Iovance operates within the competitive advanced cell therapy sector, facing direct competition from Adaptimmune Therapeutics (TCR-T therapies), Instil Bio (TIL development), and Achilles Therapeutics (precision TIL). As the first company to achieve FDA approval for a solid tumor T-cell therapy, Iovance currently holds a first-mover advantage and dominant market share in the TIL space compared to its clinical-stage peers. The leadership team is led by Frederick Vogt, Ph.D., J.D., who serves as Interim President and Chief Executive Officer, bringing extensive legal and strategic expertise in the biotechnology sector. He is supported by Jean-Marc Bellemin, Chief Financial Officer, who previously held senior roles at Gritstone Bio and Actelion, and Igor Bilinsky, Ph.D., Chief Operating Officer, who offers a background in scaling complex biopharmaceutical operations from Oncternal Therapeutics. The company’s strategic direction is heavily influenced by its Board of Directors, which includes notable figures such as Wayne P. Rothbaum, a prominent biotech investor and founder of Quentis Therapeutics, and Merrill A. McPeak, former Chief of Staff of the U.S. Air Force. Institutional backing remains strong, with significant positions held by major investment firms including Perceptive Advisors, BlackRock, and Vanguard, reflecting confidence in the company’s specialized manufacturing infrastructure and commercial scaling capabilities.